The OBR Video Center Features educational videos covering a wide range of oncology specific topics.
Dr. Damjanov, Chief of GI Oncology at Abramson Cancer Center at Penn Presbyterian, discusses identifying subgroups of patients for targeted therapies in HCC
Published: 21 January 2017
Robert A. Figlin, MD, on the trade-offs between safety & efficacy when discussing 1st line RCC
Dr. Figlin regarding the trade-offs between safety and efficacy when discussing first-line renal cell carcinoma (RCC) treatment options.
Robert A. Figlin, MD, on the convenience factor of oral TKIs & treatment decisions in advanced RCC
Dr. Figlin offers opinion on whether the convenience of oral TKIs influences treatment decisions in advanced renal cell cancer patients.
Robert A. Figlin, MD, on how checkpoint inhibitors figure into treatment for 1st line RCC patients
Dr. Figlin on how checkpoint inhibitors figure into treatment algorithms for unresectable 1st line renal cell carcinoma (RCC) patients
Robert A. Figlin, MD, on deciding which metastatic RCC patients should get a TKI as 1st line therapy
Dr. Figlin on deciding which metastatic RCC patients should get a TKI as first line therapy
Robert A. Figlin, MD, provides perspective on I-O failures
Dr. Figlin considers the best course of action if a newly diagnosed advanced renal cell carcinoma (RCC) patient receives nivolumab ...
Walter Stadler, MD, considers which mRCC patients should receive a TKI as 1st line therapy
Dr. Stadler on deciding which metastatic renal cell carcinoma (mRCC) patients should receive a TKI as 1st line therapy
Walter Stadler, MD, on treating RCC in the 2nd line setting following I-O failure
Dr. Stadler elaborates on how an advanced renal cell carcinoma (RCC) patient should be treating in the 2nd line setting ...
Walter Stadler, MD, regarding TKIs in the treatment of renal cell carcinoma
Dr. Stadler comments on whether TKIs used in the treatment of renal cell carcinoma (RCC) are interchangeable and which seem ...
Walter Stadler, MD, comments on the PROSPER & SPARTAN studies in prostate cancer
Dr. Stadler elaborates on the outcomes of the PROSPER and SPARTAN studies in non-metastatic castrate-resistant prostate cancer
Walter Stadler, MD, on immunotherapy and prostate cancer treatment algorithms
Dr. Stadler tells us how immunotherapy is being integrated into castrate resistant prostate cancer treatment algorithms
